Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Japan.
ARK Resource Co, Ltd, Kumamoto, Japan.
FASEB J. 2024 May 31;38(10):e23656. doi: 10.1096/fj.202301864RR.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Obesity is a major risk factor for the development of COVID-19. Angiotensin-converting enzyme 2 (ACE2) is an essential receptor for cell entry of SARS-CoV-2. The receptor-binding domain of the S1 subunit (S1-RBD protein) in the SARS-CoV-2 spike glycoprotein binds to ACE2 on host cells, through which the virus enters several organs, including the lungs. Considering these findings, recombinant ACE2 might be utilized as a decoy protein to attenuate SARS-CoV-2 infection. Here, we examined whether obesity increases ACE2 expression in the lungs and whether recombinant ACE2 administration diminishes the entry of S1-RBD protein into lung cells. We observed that high-fat diet-induced obesity promoted ACE2 expression in the lungs by increasing serum levels of LPS derived from the intestine. S1-RBD protein entered the lungs specifically through ACE2 expressed in host lungs and that the administration of recombinant ACE2 attenuated this entry. We conclude that obesity makes hosts susceptible to recombinant SARS-CoV-2 spike proteins due to elevated ACE2 expression in lungs, and this model of administering S1-RBD protein can be applied to new COVID-19 treatments.
新型冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的。肥胖是 COVID-19 发展的一个主要危险因素。血管紧张素转化酶 2(ACE2)是 SARS-CoV-2 进入细胞的必需受体。SARS-CoV-2 刺突糖蛋白的 S1 亚基(S1-RBD 蛋白)的受体结合域与宿主细胞上的 ACE2 结合,通过该途径病毒进入包括肺在内的多个器官。鉴于这些发现,重组 ACE2 可能被用作诱饵蛋白来减轻 SARS-CoV-2 感染。在这里,我们研究了肥胖是否会增加肺部 ACE2 的表达,以及重组 ACE2 给药是否会减少 S1-RBD 蛋白进入肺细胞。我们观察到,高脂肪饮食诱导的肥胖通过增加来自肠道的 LPS 血清水平促进肺部 ACE2 的表达。S1-RBD 蛋白通过宿主肺中表达的 ACE2 特异性进入肺部,而重组 ACE2 的给药可减弱这种进入。我们得出结论,肥胖使宿主容易受到重组 SARS-CoV-2 刺突蛋白的影响,这是由于肺部 ACE2 表达升高所致,并且这种 S1-RBD 蛋白给药模型可应用于新的 COVID-19 治疗。